Login to Your Account



Other News To Note


Wednesday, November 30, 2011
• Civitas Therapeutics Inc., of Chelsea, Mass., received a grant from The Michael J. Fox Foundation for Parkinson's Research to support clinical development of its lead Parkinson's disease candidate CVT-301, an inhaled formulation of levodopa (L-dopa). Privately held Civitas did not disclose the funding amount, but said it would support studies of CVT-301 through proof of concept, expected to conclude by year-end 2012.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription